Suppr超能文献

中国皮肤科医生对特应性皮炎外用抗炎药的认知及影响其选择的因素:一项横断面调查研究

Dermatologists' Perceptions and Factors Influencing the Selection of Topical Anti-Inflammatory Agents for Atopic Dermatitis in China: A Cross-Sectional Survey Study.

作者信息

Hu Jian, Jia Qiuyu, Zhang Wenge, Zhang Jianzhong, Li Houmin

机构信息

Department of Dermatology, Peking University People's Hospital, Beijing, People's Republic of China.

出版信息

Clin Cosmet Investig Dermatol. 2024 Nov 28;17:2713-2723. doi: 10.2147/CCID.S487996. eCollection 2024.

Abstract

OBJECTIVE

Topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE-4) inhibitors are three common topical anti-inflammatory agents for treating atopic dermatitis (AD). The purpose of our study was to understand Chinese dermatologists' perceptions and the factors influencing their choices of the three agents.

METHODS

An online questionnaire survey was conducted between 25 July 2022 and 25 August 2022 among Chinese dermatologists. The survey with six multiple-choice questions focused on what were their most commonly prescribed agents for treating AD, and what factors influenced their choices of the three agents. The results were assessed by chi-square test and logistic regression analysis.

RESULTS

A total of 1, 156 valid questionnaire replies were received. For treating AD, 79.84% of Chinese dermatologists chose TCS, 81.40% chose TCI, and 18.25% chose PDE-4 inhibitors. When TCS was not chosen, the three principal reasons included local adverse effects (85.56%), suspicious infection on lesioned area (71.54%), and patient steroid phobia (61.59%). Coincidentally, when the TCI and PDE-4 inhibitors were chosen, the main reason was patient steroid phobia (76.21% and 74.74% respectively) against TCS. When PDE-4 inhibitors were not chosen, the major reasons were their intolerable adverse effects (80.36%) and their slower onset and weak efficacy (57.61%). Logistic regression analysis revealed that more senior dermatologists were less likely to choose TCS for the reason of local adverse effects and patient steroid phobia (each < 0.05), they were more likely to choose TCI for the same reason of patient steroid phobia against TCS ( < 0.05).

CONCLUSION

Local adverse effects and patient steroid phobia were the reasons that limited Chinese dermatologists from choosing TCS for treating AD. Instead, more of them choose to use TCI. PDE-4 inhibitors were sometimes considered as an alternative to TCS or TCI, but its local adverse effects and limited efficacy affected the choice of this agent.

摘要

目的

外用糖皮质激素(TCS)、外用钙调神经磷酸酶抑制剂(TCI)和磷酸二酯酶4(PDE - 4)抑制剂是治疗特应性皮炎(AD)的三种常见外用抗炎药。我们研究的目的是了解中国皮肤科医生对这三种药物的看法以及影响他们选择的因素。

方法

于2022年7月25日至2022年8月25日对中国皮肤科医生进行了一项在线问卷调查。该调查有六个多项选择题,重点关注他们治疗AD最常用的药物是什么,以及哪些因素影响了他们对这三种药物的选择。结果通过卡方检验和逻辑回归分析进行评估。

结果

共收到1156份有效问卷回复。对于治疗AD,79.84%的中国皮肤科医生选择TCS,81.40%选择TCI,18.25%选择PDE - 4抑制剂。当未选择TCS时,三个主要原因包括局部不良反应(85.56%)、皮损部位疑似感染(71.54%)和患者激素恐惧症(61.59%)。巧合的是,当选择TCI和PDE - 4抑制剂时,主要原因是患者对TCS的激素恐惧症(分别为76.21%和74.74%)。当未选择PDE - 4抑制剂时,主要原因是其难以耐受的不良反应(80.36%)以及起效较慢和疗效较弱(57.61%)。逻辑回归分析显示,更资深的皮肤科医生因局部不良反应和患者激素恐惧症而不太可能选择TCS(均<0.05),出于患者对TCS的激素恐惧症这一相同原因,他们更有可能选择TCI(<0.05)。

结论

局部不良反应和患者激素恐惧症是限制中国皮肤科医生选择TCS治疗AD的原因。相反,他们更多地选择使用TCI。PDE - 4抑制剂有时被视为TCS或TCI的替代品,但其局部不良反应和有限的疗效影响了对该药物的选择。

相似文献

2
Topical anti-inflammatory treatments for eczema: network meta-analysis.
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015064. doi: 10.1002/14651858.CD015064.pub2.
3
A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis.
J Allergy Clin Immunol Pract. 2023 May;11(5):1347-1359. doi: 10.1016/j.jaip.2023.03.022. Epub 2023 Mar 29.
5
Attitudes of Australian dermatologists to the use and safety of topical corticosteroids in paediatric atopic dermatitis.
Australas J Dermatol. 2016 Nov;57(4):278-283. doi: 10.1111/ajd.12402. Epub 2015 Sep 22.
6
Topical Corticosteroid Phobia among Parents of Children with Atopic Eczema in Korea.
Ann Dermatol. 2015 Oct;27(5):499-506. doi: 10.5021/ad.2015.27.5.499. Epub 2015 Oct 2.
10
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
Dermatol Ther (Heidelb). 2024 Nov;14(11):3161-3174. doi: 10.1007/s13555-024-01272-3. Epub 2024 Oct 7.

本文引用的文献

1
Topical Treatments in Atopic Dermatitis: An Expansive Review.
J Clin Med. 2024 Apr 10;13(8):2185. doi: 10.3390/jcm13082185.
2
Atopic dermatitis: A global health perspective.
J Eur Acad Dermatol Venereol. 2024 May;38(5):801-811. doi: 10.1111/jdv.19723. Epub 2023 Dec 27.
3
Epidemiology of mental health comorbidity in patients with atopic dermatitis: An analysis of global trends from 1998 to 2022.
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):496-512. doi: 10.1111/jdv.19686. Epub 2023 Dec 11.
4
Topical Therapies for Atopic Dermatitis.
JAMA. 2023 Nov 14;330(18):1791-1792. doi: 10.1001/jama.2023.17719.
5
English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021.
J Dermatol. 2022 Oct;49(10):e315-e375. doi: 10.1111/1346-8138.16527. Epub 2022 Aug 22.
6
Management of atopic dermatitis: a narrative review.
Med J Aust. 2022 Jun 20;216(11):587-593. doi: 10.5694/mja2.51560. Epub 2022 May 29.
7
Optimizing topical management of atopic dermatitis.
Ann Allergy Asthma Immunol. 2022 May;128(5):488-504. doi: 10.1016/j.anai.2022.03.004. Epub 2022 Mar 12.
8
The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019.
World Allergy Organ J. 2021 Nov 9;14(11):100604. doi: 10.1016/j.waojou.2021.100604. eCollection 2021 Nov.
9
Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons.
Am J Clin Dermatol. 2021 Nov;22(6):775-783. doi: 10.1007/s40257-021-00629-0. Epub 2021 Jul 28.
10
Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions.
Am J Clin Dermatol. 2021 Nov;22(6):837-851. doi: 10.1007/s40257-021-00623-6. Epub 2021 Jul 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验